MaaT Pharma is a microbiome–based pharmaceutical company revolutionizing and shaping individualize
Location: France
Employees: 11-50
Phone: +33 9 53 41 39 65
Total raised: $93.16M
Founded date: 2014
Investors 2
| Date | Name | Website |
| - | Credit Mut... | creditmutu... |
| - | SymBiosis | symbiosis.... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 30.07.2025 | - | $43.86M | European I... |
| 02.12.2020 | Series B | $29.5M | - |
| 05.02.2020 | Series B | $19.8M | - |
Mentions in press and media 12
| Date | Title | Description |
| 14.11.2025 | MaaT Pharma announces the successful completion of its Global Offering of €9.1 million | MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated... |
| 30.07.2025 | MaaT Pharma: €37.5 Million EIB Loan Secured To Advance Cancer Therapies | MaaT Pharma, a clinical-stage biotechnology company focused on Microbiome Ecosystem Therapies (MET) for cancer patients, has secured a €37.5 million loan from the European Investment Bank (EIB) to advance its late-stage hemato-oncology prog... |
| 14.05.2024 | MaaT Pharma Launches a Global Offering of approximately 18 Million Euros | MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotech company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to... |
| 11.08.2022 | One year into clinical hold, FDA has more questions about 'pooled' microbiome therapy | The FDA is still wary about a trial testing a microbiome therapy in patients with steroid-resistant acute graft-versus-host disease (aGVHD). A year after MaaT Pharma’s IND application in the US was first met with a clinic... |
| 02.12.2020 | MaaT Pharma Raises €7.35M Series B Extension; Closes €25.35M Round | MaaT Pharma, a Lyon, France-based clinical stage company, raised an additional €7.35m in ($8.7m) in Series B financing round, bringing the total raised in this round to €25.35m. The round was led by PSIM Fund, managed by Bpifrance on behalf... |
| 02.12.2020 | French startup lands $8.7M to advance microbiome therapies | Clinical Care Capacity Planning Learn how to manage clinical care capacity more efficiently during uncertain times. SAP Promoted Telemedicine’s potential to provide healthcare to the world’s most vulnerable Teladoc Health Head of R&D Yu... |
| 01.12.2020 | MaaT Pharma : Announces Series B Extension and Final Closing with Total of 25 Million ($29.5 Million) | MaaT Pharma announced today that the company secured an additional €7.35 million ($8.7 million) in an extension of its Series B financing round, bringing the total raised in this round to €25.35 million. The new capital from the PSIM Fund m... |
| 05.02.2020 | MaaT Pharma Raises €18M in Series B Financing | MaaT Pharma, a Lyon, France-based clinical stage company, raised €18m in Series B financing. Backers included SymBiosis, and existing investors Seventure Partners, Crédit Mutuel Innovation, and Biocodex. Led by Hervé Affagard, co-founder an... |
| 17.04.2019 | As researchers pursue links between bacteria and human health, startups stand to benefit | In 2009, the National Institutes of Health launched a five-year, $150 million project to stimulate research into a new field of medicine examining the connections between the millions of bacteria living in the human gut and overall human he... |
| 09.01.2015 | Seventure invests EUR 1 M (USD 1.25 M) in First Investment Round for MaaT Pharma™ | Seventure Partners, one of Europe’s leaders in financing innovation, announces today its investment in MaaT Pharma™, a newly founded French microbiome company. Seventure... |
Show more